Literature DB >> 16837865

Assessment of the association between HIV viral load and CD4 cell count on the occurrence of oropharyngeal candidiasis in HIV-infected patients.

Donald E Mercante1, Janet E Leigh, Elizabeth A Lilly, Kelly McNulty, Paul L Fidel.   

Abstract

BACKGROUND: Oropharyngeal candidiasis (OPC) is the most frequently observed oral infection in HIV-infected individuals. Historically, lower CD4 counts have been associated with an increased prevalence of OPC in HIV-infected patients, but HIV viral load has also recently been recognized as a possible predictive factor.
OBJECTIVE: We examined the impact of viral load and blood CD4 cell count on the occurrence of OPC using modern exploratory statistical analyses.
METHODS: The exploratory and inferential methods of classification and regression trees (CARTs) and logistic regression were used to compare the impact of viral load and CD4 cell counts on OPC status in 161 HIV-infected individuals from an outpatient clinic population in New Orleans.
RESULTS: The use of stepwise logistic regression and CART to classify individual OPC status both identified viral load as the most important covariate, followed by CD4 cells counts. Age, sex, and highly active antiretroviral therapy use were also found to be associated with OPC status.
CONCLUSIONS: These data strongly suggest that low viral load distinguishes those not at risk for OPC with high viral load, which also includes a heterogeneous set of predictors for OPC status, has the highest impact on OPC classification.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837865     DOI: 10.1097/01.qai.0000225011.76439.99

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

1.  Macrophage-mediated responses to Candida albicans in mice expressing the human immunodeficiency virus type 1 transgene.

Authors:  Mathieu Goupil; Emilie Bélanger Trudelle; Véronique Dugas; Catherine Racicot-Bergeron; Francine Aumont; Serge Sénéchal; Zaher Hanna; Paul Jolicoeur; Louis de Repentigny
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

2.  Lung microbiomes: new frontiers?

Authors:  Kathryn DeRiemer; George Thompson
Journal:  Am J Respir Crit Care Med       Date:  2015-04-15       Impact factor: 21.405

3.  Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis.

Authors:  Theo S Plantinga; Omar J M Hamza; Janet A Willment; Bart Ferwerda; Nicole M D van de Geer; Paul E Verweij; Mecky I N Matee; Kathy Banahan; Luke A J O'neill; Bart-Jan Kullberg; Gordon D Brown; André J A M van der Ven; Mihai G Netea
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

Review 4.  Oropharyngeal candidiasis in the era of antiretroviral therapy.

Authors:  George R Thompson; Payal K Patel; William R Kirkpatrick; Steven D Westbrook; Deborah Berg; Josh Erlandsen; Spencer W Redding; Thomas F Patterson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-02-13

Review 5.  Oropharyngeal Candidiasis in HIV Infection: Analysis of Impaired Mucosal Immune Response to Candida albicans in Mice Expressing the HIV-1 Transgene.

Authors:  Louis de Repentigny; Mathieu Goupil; Paul Jolicoeur
Journal:  Pathogens       Date:  2015-06-23

6.  Defective IL-17- and IL-22-dependent mucosal host response to Candida albicans determines susceptibility to oral candidiasis in mice expressing the HIV-1 transgene.

Authors:  Mathieu Goupil; Vincent Cousineau-Côté; Francine Aumont; Serge Sénéchal; Louis Gaboury; Zaher Hanna; Paul Jolicoeur; Louis de Repentigny
Journal:  BMC Immunol       Date:  2014-10-26       Impact factor: 3.615

7.  Epidemiology and Prevalence of Oral Candidiasis in HIV Patients From Chad in the Post-HAART Era.

Authors:  Liliane Taverne-Ghadwal; Martin Kuhns; Timo Buhl; Marco H Schulze; Weina Joseph Mbaitolum; Lydia Kersch; Michael Weig; Oliver Bader; Uwe Groß
Journal:  Front Microbiol       Date:  2022-02-17       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.